ArticleCNS neuroscience & therapeutics2026
The Protective Mechanism of Continuous Theta Burst Stimulation in the Acute Phase of Stroke Through Modulation of the Calcineurin/AKT/FOXO1 Signaling Pathway.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsTo investigate the neuroprotective effects of continuous theta-burst stimulation (cTBS) during the acute phase of ischemic stroke and its impact on neuronal apoptosis in the peri-infarct region.
methodsMCAO was induced in mice using the Longa method. cTBS was administered daily for seven days. Motor function and limb coordination were assessed behaviorally. Transcriptomic and proteomic analyses of the peri-infarct region were performed to explore mechanisms. Immunofluorescence and Western blot analyzed key proteins in the calcineurin/AKT/FOXO1 pathway, while TUNEL staining assessed neuronal apoptosis. AAV-mediated gene knockdown was used to validate the pathway's role in apoptosis.
resultscTBS improved motor performance, reduced infarct volume, and preserved peri-infarct tissue architecture. It suppressed calcineurin expression, enhanced calcineurin/AKT/FOXO1 pathway activation, and decreased neuronal apoptosis.
conclusioncTBS exerts neuroprotection by modulating the calcineurin/AKT/FOXO1 pathway, ultimately inhibiting neuronal apoptosis in the peri-infarct region.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.